A novel platelet activating factor antagonist, SM-12502, attenuates endotoxin-induced disseminated intravascular coagulation and acute pulmonary vascular injury by inhibiting TNF production in rats

Thrombosis and Haemostasis

Volumn 75, Issue 6, 1996, Pages 965-970

  Murakami, Kazunori ^a   Okajima, Kenji ^a   Uchiba, Mitsuhiro ^a   Johno, Masayoshi ^a   Okabe, Hiroaki ^a   Takatsuki, Kiyoshi ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3,5 DIMETHYL 2 (3 PYRIDYL) 4 THIAZOLIDINONE; ENDOTOXIN; FIBRIN; FIBRINOGEN; FIBRINOGEN DEGRADATION PRODUCT; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL INJURY; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LUNG BLOOD VESSEL; LUNG EDEMA; MALE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RAT; SEPSIS;

EID: 0029987315     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650402     Document Type: Article

References (43)

1. Parrillo JE. Pathogenetic mechanisms of septic shock, N Engl J Med 1993; 328: 1471-7.
2. St. John RC, Dorinsky PM. Immunologic therapy for ARDS, septic shock, and multiple organ failure. Chest 1993; 103: 932-43.
3. Bone RC, Ursprung R, Slotman G, Maunder R, Silverman H, Hyers TM, Kerstein MD. Adult respiratory distress syndrome. Chest 1992; 101: 320-6.
4. Okajima K, Fujise R, Motosato Y, Ushijima M, Okabe H, Takatsuki K. Plasma levels of granulocyte elastase-α1-proteinase inhibitor complex in patients with disseminated intravascular coagulation: Pathophysiologic implications. Am J Hematol 1994; 47: 82-8.
5. Dhainaut JF, Mira JP, Brunet F. Platelet-activating factor antagonists as therapeutic strategy in sepsis. Progr Clin Biol Res 1994; 388: 277-93.
6. Koltai M, Hosford D, Braquet P. Role of PAF and cytokines in microvascular tissue injury. J Lab Clin Med 1992; 119: 461-6.
7. Wendmore CV, Williams TJ. Platelet-activating factor (PAF), a secretory product of polymorphonuclear leukocytes, increases vascular permeability in rabbit skin. Br J Pharmacol 1981; 74: 916-8.
8. Chang SW, Feddersen CO, Henson PM, Voelkel NF. Platelet-activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats. J Clin Invest 1987; 79: 1498-509.
9. Bessin P, Bonnet J, Apffel D, Soulard C, Desgroux L, Pelas I, Benveniste J. Acute circulatory collapse caused by platelet activating factor (PAF-acether) in dogs. Eur J Pharmacol 1983; 86: 403-13.
10. Terashita Z, Imura Y, Nishikawa K, Sumida S. Is platelet activating factor a mediator of endotoxic shock? Eur J Pharmacol 1985; 109: 257-61.
11. Doebber TW, Wu MS, Robbins JC, Choy BM, Chang MN, Shen TY. Platelet activating factor involvement in endotoxin-induced hypotension in rats: studies with PAF-receptor antagonist kadsurenone. Biochem Biophys Res Commun 1985; 127: 799-808.
12. Salari H, Demos M, Wong A. Comparative hemodynamics and cardiovascular effects of endotoxin and platelet-activating factor in rat. Circ Shock 1990; 32: 189-207.
13. Rabinovici R, Esser KM, Lysko PG, Yue TL, Griswold DE, Hillegass LM, Bugelski PJ, Hallenbeck JM, Feuerstein G. Priming by platelet-activating factor of endotoxin-induced lung injury and cardiovascular shock. Circ Res 1991; 69: 12-25.
14. Bone RC. Modulators of coagulation, a critical appraisal of their role in sepsis. Arch Intern Med 1992; 152: 1381-9.
15. Dhainaut JA, Tenaillon A, Tulzo YL, Schlemmer B, Solet JP, Wolff M, Holzapfel L, Zeni F, Dreyfuss D, Mira JP, De Vathaire F, Guinot P. Platelet-activating factor receptor antagonist BN52021 in the treatment of severe sepsis: A randomized, double-blind, placebo-controlled, multicenter clinical trial. Crit Care Med 1994; 22: 1720-8.
16. Koike H, Imanishi N, Natsume Y, Morooka S. Effects of platelet activating factor (PAF) receptor antagonists on intracellular platelet activating factor function in neutrophils. Eur J Pharmacol 1994; 269: 299-309.
17. Imanishi N, Komuro Y, Morooka S. Effect of a selective PAF antagonist SM-10661 ((±)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one HCl) on experimental disseminated intravascular coagulation (DIC). Lipids 1991; 26: 1391-5.
18. Uchiba M, Okajima K, Murakami K, Okabe H, Takatsuki K. Endotoxin- induced pulmonary vascular injury is mainly mediated by activated neutrophils in rats. Thromb Res 1995; 78: 117-25.
19. Mulligan MS, Varani J, Dame MK, Lane CL, Smith CW, Anderson DC, Ward PA. Role of endothelial-leukocyte adhesion molecule 1 (ELAM-1) in neutrophil-mediated lung injury in rats. J Clin Invest 1991; 88: 1396-406.
20. Chang SW, Ohara N, Kuo G, Voelkel NF. Tumor necrosis factor-induced lung injury is not mediated by platelet-activating factor. Am J Physiol 1989; 257: L232-L239.
21. Imanishi N, Murakami-Uchida M, Koike H, Natsume Y, Morooka S. Biological effects of the new platelet-activating factor receptor antagonist (+)-cis-3,5-dimethyl-2-(3-pyridyl) thiazolidin-4-one hydrochloride. Arzneim-Forsch/Drug Res 1994; 44: 317-22.
22. Warr TA, Rao LVM, Rapaport SI. Disseminated intravascular coagulation in rabbits induced by administration of endotoxin or tissue factor: effect of anti-tissue factor antibodies and measurement of plasma extrinsic pathway inhibitor activity. Blood 1990; 75: 1481-89.
23. Okajima K, Ueyama H, Hashimoto Y, Sasaki Y, Matsumoto K, Okabe H, Araki S, Takatsuki K. Homozygous variant of antithrombin in that lacks affinity for heparin: ATIII Kumamoto. Thromb Haemost 1989; 61: 20-4.
24. Zhang X, Ellis EF. Superoxide dismutase reduces permeability and edema induced by hypertension in rats. Am J Physiol 1990; 259: H497-H503.
25. Ford TC, Rickwood D. Formation of isotonic Nycodenz gradients for cell separations. Anal Biochem 1982; 124: 293-8.
26. Westlin WF, Gimbrone Jr MA. Neutrophil-mediated damage to human vascular endothelium. Role of cytokine activation. Am J Pathol 1993; 142: 117-28.
27. Levi M, ten Cate H, van der Poll T, van Deventer SJH. Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA 1993; 270: 975-9.
28. Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS, Gimbrone Jr MA. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: Characterization and comparison with the actions of interleukin 1. Proc Nail Acad Sci USA 1986; 83: 4533-7.
29. Moore KI, Esmon CT, Esmon NL. Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the cell surface of bovine aortic endothelial cells in culture. Blood 1989; 73: 159-65.
30. Kobayashi M, Shimada K, Ozawa T. Human recombinant interleukin-1- and tumor necrosis factor-mediated supression of heparin-like compounds on cultured porcine aortic endothelial cells. J Cell Physiol 1990; 144: 383-90.
31. Fajardo LF. The complexity of endothelial cells. Am J Clin Pathol 1989; 92: 241-50.
32. Van Der Poll T, Büller HR, ten Cate H, Wortel CH, Bauer KA, van Deventer SJH, Hack CE, Sauerwein HP, Rosenberg RD, ten Cate JW. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990; 322: 1622-7.
33. Ikejima T, Okusawa S, Ghezzi P, van der Meer JWM, Dinarello CA. Interleukin-1 induces tumor necrosis factor (TNF) in human peripheral blood mononuclear cells in vitro and a circulating TNF-like activity in rabbits. J Infect Dis 1990; 162: 215-23.
34. Okusawa S, Yancey KB, van der Meer JWM, Endres S, Lonnemann G, Hefter K, Frank MM, Burke JF, Dinarello CA, Gelfand JA. C5a stimulates secretion of tumor necrosis factor from human mononuclear cells in vitro. J Exp Med 1988; 168: 443-8.
35. Suzuki N, Ishii Y, Kitamura S. Mechanism for the increased permeability in endothelial monolayers induced by elastase. Mediators of Inflammation 1994; 3: 11-6.
36. Pober JS, Cotran RS. The role of endothelial cells in inflammation. Transplantation 1990; 50: 537-44.
37. Ferrari-Baliviera E, Mealy K, Smith RJ, Wilmore DW. Tumor necrosis factor induces adult respiratory distress syndrome in rats. Arch Surg 1989; 124: 1400-5.
38. Stephens KE, Ishizaka A, Larrick JW, Raffin TA. Tumor necrosis factor causes increased pulmonary permeability and edema. Am Rev Respir Dis 1988; 137: 1364-70.
39. Windsor AC, Walsh CJ, Mullen PG, Cook DJ, Fisher BJ, Blocher CR, Leeper-Woodford SK, Sugerman HJ, Fowler III AA. Tumor necrosis factor-α blockade prevents neutrophil CD18 receptor upregulation and attenuates acute lung injury in porcine sepsis without inhibition of neutrophil oxygen radical generation. J Clin Invest 1993; 91: 1459-68.
40. Dubois C, Bissonnette E, Rola-Pleszczynski M. Platelet-activating factor (PAF) enhances tumor necrosis factor production by alveolar macrophages. Prevention by PAF receptor antagonists and lipoxygenase inhibitors. J Immunol 1989; 143: 964-70.
41. Hunyadi J, Kenderessy AS, Duda E, Braquet P, Dobozy A. Platelet- activating factor antagonists (BN52021 and BN50730) inhibit tumor necrosis factor-alpha-mediated cytotoxity on murine L929 tumor cells. Molecular Immunology 1993; 30: 517-19.
42. Rabinovici R, Esser KM, Lysko PG, Yue TL, Griswold DE, Hillegass LM, Bugelski PJ, Hallenbeck JM, Feuerstein G. Priming by platelet-activating factor of endotoxin-induced lung injury and cardiovascular shock. Circ Res 1991; 69: 12-25.
43. Weyrich AS, McIntyre TM, McEver RP, Prescott SM, Zimmerman GA. Monocyte tethering by P-selectin regulates monocyte chemotactic protein-1 and tumor necrosis factor-α secretion. Signal integration and NF-κB translocation. J Clin Invest 1995; 95: 2297-303.